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ABSTRACT 
The purpose of this research was to prepare a floating drug delivery system of famotidine. The floating microspheres can be prepared for the 
improvement of absorption and bioavailability of famotidine by retaining the system in the stomach for prolonged period of time. Floating 
microspheres of famotidine were prepared using different polymers like ethyl cellulose, hydroxy propyl methyl cellulose by so lvent diffusion-
evaporation method. The microspheres had smooth surfaces with free-flowing and good-packing properties. The yield of the microspheres was 
up to 73.32±0.14% and ethyl cellulose microspheres entrapped the maximum amount of the drug. Scanning electron microscopy confirmed 
their hollow structures with sizes in 331.6 nm. The prepared microspheres exhibited prolonged drug release and Percentage buoyancy was 
found to 73.25±0.23. The formulated batches were evaluated for percentage yield, particle size measurement, flow properties, percent 
entrapment efficiency, swelling studies. The formulations were subjected to stability studies and In-vitro release and release kinetics data was 
subjected to different dissolution models. It was concluded that developed floating microspheres of famotidine offers a suitable and practical 
approach for prolonged release of drug over an extended period of time and thus oral bioavailability, efficacy and patient co mpliance is 
improved. 
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INTRODUCTION 
Oral rout of administration is the most convenient and 
widely used method of drug administration and the 
development of stomach specific oral controlled-release drug 
delivery systems is a challenging job due to the variation of 
pH in different segments of the gastrointestinal tract, the 
fluctuation in gastric emptying time and the difficulty of 
localizing an oral delivery system in a selected region of the 
gastrointestinal tract. Rapid gastrointestinal transit can 
prevent the absorption of complete drug in the absorption 
zone and reduce the efficacy of the administered dose since 
the majority of drugs are absorbed in stomach or the upper 
part of small intestine1, 2. To overcome the above discussed 
issues, many types of oral controlled drug delivery systems 
having prolonged gastric residence times have been reported 
such as: floating drug dosage systems (FDDS)3-7, swelling or 
expanding system8, mucoadhesive systems 9,10 modified-
shape systems 11, high-density systems and other delayed 
gastric emptying devices 12. FDDS have lower density than 
gastric fluids and thus remain buoyant in the stomach fluid 
without affecting the gastric emptying for a prolonged period 
of time. While the system is floating in the gastric fluid, the 
drug is released slowly from the system at a desired rate. 
Materials used for FDDS include carbon dioxide gas-forming 
agents (carbonate or bicarbonate compounds) 8,13, highly 
swellable hydrocolloids and light mineral oils14,15. Multiple 
unit systems and floating systems prepared by solvent 
evaporation methods have also been developed12, 16-20. 
However, it has been shown that products based on a 
multiple unit system comprising many small units have 
advantages over single -unit preparations such as matrix 
tablets21. The gastric emptying of multiple unit dosage forms 
occur gradually, in a more consistent manner, with less 
individual variation2,22. Multiple unit dosage forms also have 
the potential to distribute widely over a large area in the 
stomach and small intestine, thus yielding a more predictable 
drug release by suppressing the effect of many variables in 
the gastrointestinal environment. As multiple unit dosage 
forms consist of many small units, less risk of dosage 
dumping is expected23.Famotidine, a competitive histamine 
H2-receptor antagonist is used to treat gastrointestinal 
disorders such as gastric or duodenal ulcer, 
gastroesophageal reflux disease, and pathological 
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hypersecretory conditions. Famotidine inhibits many of the 
isoenzymes of the hepatic CYP450 enzyme system. Other 
actions of famotidine include an increase in gastric bacterial 
flora such as nitrate-reducing organisms24. Famotidine is 
widely used as the treatment of peptic ulcer disease and 
gastroesophageal reflux disease. Famotidine binds 
competitively to H2- receptors located on the basolateral 
membrane of the parietal cell, blocking histamine affects. 
This competitive inhibition results in reduced basal and 
nocturnal gastric acid secretion and a reduction in gastric 
volume, acidity, and amount of gastric acid released in 
response to stimuli including food, caffeine, insulin, betazole 
and pentagastrin 25. Floating microspheres are one of the 
multiparticulate delivery system and are prepared to obtain 
prolonged or controlled drug delivery to improve 
bioavailability and to target drug to specific sites. 
Microspheres can also offer advantages like limiting 
fluctuation within therapeutic range, reducing site effects, 
decreasing dosing frequency and improving patient 
compliance26. 
MATERIAL AND METHODS 
Material 
Famotidine was a gift sample from Pharmaceuticals 
Company.  Dichloromethane, ethanol and isopropyl alcohol 
were purchased from E. Merck (India) Ltd., Mumbai. Ethyl 
cellulose, hydroxyl propyl methyl cellulose was purchased 
from Loba Chem. Pvt. Ltd, Mumbai. Double distilled water 
was prepared freshly and used whenever required. All the 
chemicals used in this work were of analytical grade. 
 
 
 
Methods 
Determination of absorption maxima  
A solution of containing the concentration 10μg/ml was 
prepared in 0.1N HCl. UV spectrum was taken using Double 
beam UV/VIS spectrophotometer (Labindia-3000+). The 
solution was scanned in the range of 200-400nm.  
Preparation calibration curve  
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
0.1N HCl solution in 10 ml of volumetric flask. The resulted 
solution 1000µg/ml and from this solution 1 ml pipette out 
and transfer into 10 ml volumetric flask and volume make up 
with 0.1N HCl solution. Prepare suitable dilution to make it 
to a concentration range of 5-25μg/ml. The spectrum of this 
solution was run in 200-400 nm range in U.V. 
spectrophotometer (Labindia-3000+). Linearity of standard 
curve was assessed from the square of correlation coefficient 
(r2) which determined by least-square linear regression 
analysis. 
Preparation of floating microsphere of Famotidine 
Floating microspheres loaded with famotidine were 
prepared using solvent diffusion-evaporation method using 
HPMC and EC in different ratio like 1:0.5, 1:0.75, 1:1, 1:1.5, 
1:1.75, 1:2 w/w. Drug and polymer in proportion of drug and 
polymers were dissolved in 1:2 mixture of solvent system of 
ethanol and dichloromethane. This clear solution was poured 
slowly in a thin stream into the aqueous solution of 1% 
polyvinyl alcohol. The emulsion was continuously stirred for 
3 hrs at a speed of 500 rpm at 27±2°C. The floating 
microspheres were collected by decantation, while the non-
floating microspheres were discarded. The microspheres 
were dried overnight at 40±2°C and stored in desicator. The 
compositions of the formulations were shown in Table 1. 
 
Table 1 Formulations of the floating microspheres prepared             
Sr. No Formulation Code 
Famotidine 
(mg) 
HPMC  
(mg) 
EC 
(mg) 
1. F1 40 100 50 
2. F2 40 100 75 
3. F3 40 100 100 
4. F4 40 100 125 
5. F5 40 100 150 
6. F6 40 100 175 
7. F7 40 100 150 
8. F8 40 100 200 
 
 
Evaluation of microspheres      
Microscopic observation of prepared microsphere 
An optical microscope (cippon, Japan) with a camera 
attachment (Minolta) was used to observe the shape of the 
prepared microsphere formulation. 
Percentage yield 
The prepared microspheres with a size range of 1μm to 
1000μm were collected and weighed from different 
formulations. The measured weight was divided by the total 
amount of all non-volatile components which were used for 
the preparation of the microspheres. 
          
                                            
                                 
      
Drug entrapment 
The various formulations of the floating microspheres were 
subjected for drug content. 10 mg of floating microspheres 
from all batches were accurately weighed and crushed. The 
powder of microspheres were dissolved in 10 ml 0.1 N HCl 
and centrifuge at 1000 rpm. This supernatant solution is 
than filtered through whatmann filter paper No. 44. After 
filtration, from this solution 0.1 ml was taken out and diluted 
up to 10 ml with 0.1 N HCl. The percentage drug entrapment 
was calculated using calibration curve method 
Floating behavior 
Ten milligrams of the floating microspheres were placed in 
0.1 N HCl (100 ml). The mixture was stirred at 100 rpm in a 
magnetic stirrer. After 10 h, the layer of buoyant 
microsphere was pipetted and separated by filtration. 
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Particles in the sinking particulate layer were separated by 
filtration. Particles of both types were dried in desiccators 
until a constant weight was obtained. Both the fractions of 
microspheres were weighed and buoyancy was determined 
by the weight ratio of floating particles to the sum of floating 
and sinking particles. 
                  
                             
             
      
Measurement of mean particle size 
The mean size of the microspheres was determined by Photo 
Correlation Spectroscopy (PCS) on a submicron particle size 
analyzer (Malvern Instruments) at a scattering angle of 90°. 
A sample (0.5mg) of the microspheres suspended in 5 ml of 
distilled water was used for the measurement 
Determination of zeta potential 
The zeta potential of the drug-loaded microspheres was 
measured on a zeta sizer (Malvern Instruments) by 
determining the electrophoretic mobility in a micro 
electrophoresis flow cell. All the samples were measured in 
water at 25°C in triplicate.   
In-vitro release studies 
The drug release rate from floating microspheres was 
carried out using the USP type II (Electro Lab.) dissolution 
paddle assembly. A weighed amount of floating 
microspheres equivalent to 100 mg drug were dispersed in 
900 ml of 0.1 N HCI (pH=1.2) maintained at 37 ± 0.5°C and 
stirred at 55rpm. One ml sample was withdrawn at 
predetermined intervals and filtered and equal volume of 
dissolution medium was replaced in the vessel after each 
withdrawal to maintain sink condition. The collected 
samples analyzed spectrophotometrically at 266 nm to 
determine the concentration of drug present in the 
dissolution medium27, 28.  
Drug release kinetic data analysis 
Several kinetic models have been proposed to describe the 
release characteristics of a drug from matrix. The following 
three equations are commonly used, because of their 
simplicity and applicability. Equation 1, the zero-order 
model equation (Plotted as cumulative percentage of drug 
released vs time); Equation 2, Higuchi’s square-root equation 
(Plotted as cumulative percentage of drug released vs square 
root of time); and Equation 3, the Korsemeyer-Peppas 
equation (Plotted as Log cumulative percentage of drug 
released vs Log time). 
To study the release kinetics of Famotidinefrom the Floating 
microspheres the release data was fitted to these three 
equations 
Zero order equation 
When a graph of the cumulative percentage of the drug 
released from the matrix against time is plotted, zero order 
release is linear in such a plot, indicating that the release rate 
is independent of concentration. 
Qt = k0.t ……………………… (1) 
Where Qt is the percentage of drug released at time t and k0 is 
the release rate constant; 
First order equation 
In (100-Qt) = In 100- kI.t ………………….. (2) 
                   Where kI is the release rate constant; 
  
Higuchi’s equation (Wagner, 1969):- 
Qt = kH.t1/2    ……………………….. (3) 
                   Where KH is the Higuchi release rate constant 
Korsemeyer-Peppas 
The curves plotted may have different slopes, and hence it 
becomes difficult to exactly pin-point which curve follows 
perfect zero order release kinetics. Therefore, to confirm the 
kinetics of drug release, data were also analyzed using 
Korsemeyer’s equation. 
 Qt/Q∞ = kKP.tn 
Where Qt/ Q∞ is the fraction of drug released at time t, kKPa 
constant compromising the structural and geometric 
characteristics of the device and n is the release exponent. 
The slope of the linear curve gives the ‘n’ value. Peppas 
stated that the above equation could adequately describe the 
release of solutes from slabs, spheres, cylinders and discs, 
regardless of the release mechanism. The value of ‘n’ gives an 
indication of the release mechanism. When n = 1, the release 
rate is independent of time (typical zero order release / case 
II transport); n = 0.5 for Fickian release (diffusion/ case I 
transport); and when 0.5 < n < 1, anomalous (non-Fickian or 
coupled diffusion/ relaxation) are implicated. Lastly, when n 
> 1.0 super case II transport is apparent.  ‘n’ is the slope 
value of log Mt/M∞   versus log time curve29-31. 
Stability studies for optimized formulation 
The purpose of stability testing is to provide evidence on 
how the quality of a drug substance or drug product varies 
with time under the influence of a variety of environmental 
factors such as temperature, humidity and light and to 
establish a re-test period for the drug substance or a shelf life 
for drug product and recommended storage conditions. In 
general, a drug substance should be evaluated under storage 
condition (with appropriate tolerances) that test its thermal 
stability and if applicable, its sensitivity to moisture. Three 
types of storage conditions are used i.e. long term, 
Accelerated and where appropriate, Intermediate. 
RESULTS AND DISCUSSION 
The λ max of famotidine was found to be 266 nm by using U.V. 
spectrophotometer (Labindia-3000+) in linearity range 5-25 
µg/ml Fig.1, 2. The floating microspheres of famotidine were 
prepared by solvent diffusion-evaporation method. 
Percentage yield of different formulation was determined by 
weighing the microspheres after drying.  The percentage 
yield of different formulation was in range of 63.23±0.25 
to73.32±0.14 % Table 2. The maximum percentage yield was 
found in formulation F5, 73.32±0.14 as compare to all 
formulation. The drug entrapment efficacies of different 
formulations were in range of 62.23±0.41to 76.65±0.58 
%w/w. The maximum percentage drug entrapment was 
found in formulation F5 (76.65±0.58% w/w) Table 3. To 
assess the floating properties, the microspheres were placed 
in 0.1N hydrochloric acid. The microspheres floated for 
prolonged time over the surface of the dissolution medium 
without any apparent gelation. Buoyancy percentage of the 
microspheres was in the range of 55.56±0.41 to73.25±0.23. 
The nature of the polymer influenced the floating behaviour 
of the microspheres Table 4. The maximum percentage yield, 
drug entrapment, percentage buoyancy and floating lag time 
was found to be formulation F5 in floating microsphere. The 
optimized formulation of F5 both batches subjected to 
further studies. The mean size of the microspheres was 
determined by photo correlation spectroscopy (PCS) on a 
submicron particle size analyzer (Horiba Instruments) at a 
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scattering angle of 90°.The results of measurement of mean 
particle size of optimized formulation F5 of floating 
microsphere was found to be 331.6 nm Fig. 3. Results of zeta 
potential of optimized formulation F4 of floating 
microsphere was found -32.8 mV Fig. 4. 
 
Figure 1 U.V. Spectra of Pure Drug (Famotidine) 
 
 
Figure 2 Calibration Curve of Famotidine in 0.1 N HCl at 
266 nm 
 
 
Table 2 Percentage Yield for Different Formulation 
Formulation Percentage Yield* 
F1 65.58±0.45 
F2 68.89±0.65 
F3 63.23±0.25 
F4 68.89±0.32 
F5 73.32±0.14 
F6 69.98±0.18 
F7 68.78±0.74 
F8 65.65±0.65 
 
Table 3 Drug Entrapment for Different Formulations 
Formulation 
Drug entrapment (% w/w) 
of prepared microsphere 
F1 65.76±0.45 
F2 69.98±0.23 
F3 71.12±0.36 
F4 65.56±0.56 
F5 76.65±0.58 
F6 69.98±0.74 
F7 65.41±0.65 
F8 62.23±0.41 
*Average of three determination (n=3) 
Table 4 Percentage Buoyancy and Floating Lag Time of 
Floating Microsphere 
Formulation 
Floating Lag 
Time (Sec.) 
Percentage 
Buoyancy 
F1 69±3 62.23±0.45 
F2 78±4 60.25±0.65 
F3 65±5 61.25±0.58 
F4 98±6 65.58±0.41 
F5 32±4 73.25±0.23 
F6 49±2 62.23±0.25 
F7 88±5 55.56±0.41 
F8 98±6 65.45±0.32 
 
 
Figure 3 Particle Size Data of Optimized Microsphere Formulation F5 
 
 
Figure 4 Zeta Potential Data of Floating Microsphere F5 
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The drug release from floating microspheres was found to be 
99.89% at the end of 12 h for F2 Table 5 & Fig. 5. The In vitro 
drug release data of the optimized formulation was 
subjected to goodness of fit test by linear regression analysis 
according to zero order and first order kinetic equation, in 
order to determine the mechanism of drug release. When the 
regression coefficient values were compared, it was 
observed that an ‘r’ value of microsphere was maximum 
zero order i.e 0.989 hence indicating drug releases from 
formulations was found to follow zero order for floating 
microsphere. Table 6 and Fig.6 & 7. According to ICH 
guidelines, 3 months accelerated stability study at 40±2°C 
and 75±5% RH optimized formulations (F5) was carried out. 
It showed negligible change over time for parameters like 
appearance, drug content, dissolution and assay etc., No 
significant difference observed  in the drug content between 
initial and formulations stored at 40±2°c & 75±5% RH for 3 
months.
 
Table 5 Release Study Data of Formulation F1-F8 
Time % of Drug Release 
(hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0.5 33.25 30.25 29.98 25.65 20.23 18.23 15.65 13.23 10.23 
1 45.65 43.23 40.56 35.56 30.45 25.65 20.23 19.56 15.56 
2 55.65 49.98 45.65 40.23 38.89 35.65 30.25 25.65 23.32 
4 69.98 65.56 60.23 55.65 49.98 45.56 40.25 39.98 35.45 
6 89.98 90.25 85.65 69.98 60.23 55.56 52.23 45.56 40.23 
8 95.65 99.98 92.32 77.65 75.65 70.23 64.45 55.56 50.41 
10     99.85 96.65 85.59 82.23 80.23 63.23 60.36 
12         97.85 89.98 85.56 75.65 73.321 
 
 
Figure 5 Graph of Release Study of Formulation F1-F8 
 
Figure 6 Zero Order Release Kinetics of Optimized 
Formulation F5 
 
Figure 7 First Order Release Kinetics Optimized 
Formulation F5
Table 6 Comparative Study of Regression Coefficient for Selection of Optimized Formulation F-5 
Release 
Kinetics 
Zero order First order 
r2 0.989 0.831 
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CONCLUSION 
Floating microspheres of famotidine can be successfully 
prepared from sodium alginate by ionic gelation in 
combination with HPMC and EC for the purpose of 
gastroretentive drug delivery. On the basis of drug release, 
percentage yield, drug entrapment, percentage buoyancy and 
floating lag time F5 could be considered as promising 
formulations. Thus, the prepared floating microspheres may 
prove to be potential candidates for multiple-unit delivery 
devices adaptable to any intragastric condition. 
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